The Chemical Probes Portal: an enhanced public resource providing expert advice on chemical tools for cancer research

D. Sanfelice; A. Antolin; A. Crisp; E. Villasclaras-Fernandez; I. Mica; Y. Chen; S. Müller-Knapp; I. Collins; B. Al-Lazikani; A. M. Edwards; P. Workman

doi:10.1016/S0959-8049(22)01019-X

The Chemical Probes Portal: an enhanced public resource providing expert advice on chemical tools for cancer research

D. Sanfelice, A. Antolin, A. Crisp, E. Villasclaras-Fernandez, I. Mica, Y. Chen, S. Müller-Knapp, I. Collins, B. Al-Lazikani, A. M. Edwards, P. Workman

Genomic Medicine

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	S83
Journal	European Journal of Cancer
Volume	174
DOIs	https://doi.org/10.1016/S0959-8049(22)01019-X
State	Published - Oct 2022

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1016/S0959-8049(22)01019-X

Cite this

Sanfelice, D., Antolin, A., Crisp, A., Villasclaras-Fernandez, E., Mica, I., Chen, Y., Müller-Knapp, S., Collins, I., Al-Lazikani, B., Edwards, A. M., & Workman, P. (2022). The Chemical Probes Portal: an enhanced public resource providing expert advice on chemical tools for cancer research. European Journal of Cancer, 174, S83. https://doi.org/10.1016/S0959-8049(22)01019-X

Sanfelice, D, Antolin, A, Crisp, A, Villasclaras-Fernandez, E, Mica, I, Chen, Y, Müller-Knapp, S, Collins, I, Al-Lazikani, B, Edwards, AM & Workman, P 2022, 'The Chemical Probes Portal: an enhanced public resource providing expert advice on chemical tools for cancer research', European Journal of Cancer, vol. 174, pp. S83. https://doi.org/10.1016/S0959-8049(22)01019-X

@article{a37ff69a84b842f6887cc8c8db0dc753,

title = "The Chemical Probes Portal: an enhanced public resource providing expert advice on chemical tools for cancer research",

author = "D. Sanfelice and A. Antolin and A. Crisp and E. Villasclaras-Fernandez and I. Mica and Y. Chen and S. M{\"u}ller-Knapp and I. Collins and B. Al-Lazikani and Edwards, {A. M.} and P. Workman",

note = "Funding Information: I.C. is/was a consultant to Epidarex LLP, AdoRx Therapeutics, and Enterprise Therapeutics, and is a director of the non-profit Chemical Probes Portal. I.C. has received research funding from Astex, Merck KGaA, Janssen Biopharma, Monte Rosa Therapeutics, and Sixth Element Capital/CRT Pioneer Fund. I.C. holds stock in Monte Rosa Therapeutics AG and is a former employee of Merck Sharp & Dohme. Funding Information: P.W. is a consultant/scientific advisory board member for Alterome Therapeutics, Astex Pharmaceuticals, Black Diamond Therapeutics, CV6 Therapeutics, NextechInvest Ltd, Nuvectis Pharma, Storm Therapeutics and Vividion Therapeutics, and holds stock in Alterome, Black Diamond, Chroma Therapeutics, NextInvest, Nuvectis and Storm and is also a non-executive director of Storm a board member and executive director of the non-profit Chemical Probes Portal and a former employee of AstraZeneca. P.W. has received research funding from Astex, Cyclacel Pharmaceuticals, Merck KGaA, Nuvectis, Piramed Pharmaceuticals, Sixth Element Capital/CRT Pioneer Fund and Vernalis. ",

year = "2022",

month = oct,

doi = "10.1016/S0959-8049(22)01019-X",

language = "English (US)",

volume = "174",

pages = "S83",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - The Chemical Probes Portal

T2 - an enhanced public resource providing expert advice on chemical tools for cancer research

AU - Sanfelice, D.

AU - Antolin, A.

AU - Crisp, A.

AU - Villasclaras-Fernandez, E.

AU - Mica, I.

AU - Chen, Y.

AU - Müller-Knapp, S.

AU - Collins, I.

AU - Al-Lazikani, B.

AU - Edwards, A. M.

AU - Workman, P.

N1 - Funding Information: I.C. is/was a consultant to Epidarex LLP, AdoRx Therapeutics, and Enterprise Therapeutics, and is a director of the non-profit Chemical Probes Portal. I.C. has received research funding from Astex, Merck KGaA, Janssen Biopharma, Monte Rosa Therapeutics, and Sixth Element Capital/CRT Pioneer Fund. I.C. holds stock in Monte Rosa Therapeutics AG and is a former employee of Merck Sharp & Dohme. Funding Information: P.W. is a consultant/scientific advisory board member for Alterome Therapeutics, Astex Pharmaceuticals, Black Diamond Therapeutics, CV6 Therapeutics, NextechInvest Ltd, Nuvectis Pharma, Storm Therapeutics and Vividion Therapeutics, and holds stock in Alterome, Black Diamond, Chroma Therapeutics, NextInvest, Nuvectis and Storm and is also a non-executive director of Storm a board member and executive director of the non-profit Chemical Probes Portal and a former employee of AstraZeneca. P.W. has received research funding from Astex, Cyclacel Pharmaceuticals, Merck KGaA, Nuvectis, Piramed Pharmaceuticals, Sixth Element Capital/CRT Pioneer Fund and Vernalis.

PY - 2022/10

Y1 - 2022/10

UR - http://www.scopus.com/inward/record.url?scp=85140453534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85140453534&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(22)01019-X

DO - 10.1016/S0959-8049(22)01019-X

M3 - Article

AN - SCOPUS:85140453534

SN - 0959-8049

VL - 174

SP - S83

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

The Chemical Probes Portal: an enhanced public resource providing expert advice on chemical tools for cancer research

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this